In lab tests, GLUBLOC’s ingredients appear to help cells take up glucose even without insulin, and also improve insulin’s ability to signal cells to absorb sugar, which may contribute to lowering blood sugar.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether GLUBLOC’s modulation of insulin signaling pathways consistently correlates with improved insulin sensitivity in human trials.
A systematic review and meta-analysis of all human studies measuring insulin sensitivity (HOMA-IR, clamp) and glucose uptake markers (GLUT4 translocation, phosphorylation) in response to GLUBLOC.
Whether GLUBLOC improves insulin sensitivity in healthy adults during a hyperinsulinemic-euglycemic clamp.
A double-blind RCT with 40 healthy adults receiving GLUBLOC or placebo for 4 weeks, followed by a hyperinsulinemic-euglycemic clamp to measure whole-body insulin sensitivity and muscle GLUT4 translocation via biopsy.
Whether regular GLUBLOC use is associated with improved insulin sensitivity over time in healthy adults.
A 12-month prospective cohort study measuring HOMA-IR and fasting insulin in 500 adults using GLUBLOC daily versus 500 non-users, adjusting for diet, activity, and body composition.
Whether individuals with insulin resistance who respond to GLUBLOC have different baseline PTP1B activity than non-responders.
A case-control study comparing PTP1B expression in adipose tissue biopsies of 30 GLUBLOC responders (≥20% HOMA-IR improvement) versus 30 non-responders with prediabetes.
Whether GLUBLOC users have lower HOMA-IR or higher adipose GLUT4 expression than non-users.
A cross-sectional study measuring HOMA-IR and GLUT4 expression in adipose tissue biopsies from 100 GLUBLOC users and 100 non-users, adjusting for BMI and fasting glucose.